亚太药业
(002370)
| 流通市值：45.34亿 | | | 总市值：45.34亿 |
| 流通股本：7.46亿 | | | 总股本：7.46亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 152,074,731.41 | 64,550,537.91 | 405,174,661.29 | 306,835,789.08 |
| 营业收入 | 152,074,731.41 | 64,550,537.91 | 405,174,661.29 | 306,835,789.08 |
| 二、营业总成本 | 197,899,171.63 | 70,881,335.56 | 430,113,073.56 | 327,680,456.45 |
| 营业成本 | 103,933,891.68 | 44,313,204.73 | 278,889,830.7 | 211,419,192.11 |
| 税金及附加 | 2,595,471.25 | 1,190,216.58 | 6,385,223.42 | 4,651,222.77 |
| 销售费用 | 25,558,766.57 | 9,396,728.76 | 57,125,902.79 | 44,107,484.18 |
| 管理费用 | 28,241,851.01 | 14,465,490.73 | 53,425,235.46 | 40,838,470.04 |
| 研发费用 | 6,906,516.81 | 2,114,765.79 | 14,640,524.49 | 10,253,111.79 |
| 财务费用 | 30,662,674.31 | -599,071.03 | 19,646,356.7 | 16,410,975.56 |
| 其中:利息费用 | 34,642,973.19 | 2,464,220.63 | 30,590,222.13 | 26,373,771.94 |
| 其中:利息收入 | 4,003,460.59 | 3,076,676.55 | 11,301,468.97 | 7,048,156.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 952,429.21 | -1,408,944.07 | 1,638,089.72 | 1,045,841.69 |
| 加:投资收益 | 150,281,649.56 | - | 53,816,793.8 | 15,853,845.06 |
| 资产处置收益 | - | - | -7,367.1 | - |
| 资产减值损失(新) | -5,029,349 | -2,370,685.85 | -5,563,928.48 | -1,867,352.1 |
| 信用减值损失(新) | 865,162.2 | 420,870.66 | -32,192.56 | 83,839.38 |
| 其他收益 | 5,134,661.94 | 1,685,011.21 | 3,242,495.18 | 2,525,907.61 |
| 四、营业利润 | 106,380,113.69 | -8,004,545.7 | 28,155,478.29 | -3,202,585.73 |
| 加:营业外收入 | 57,797.8 | 1,416.11 | 11,439,832.7 | 122,290 |
| 减:营业外支出 | 1,118,577.3 | 11,424.73 | 5,109,816.2 | 222,358.49 |
| 五、利润总额 | 105,319,334.19 | -8,014,554.32 | 34,485,494.79 | -3,302,654.22 |
| 减:所得税费用 | 142,864.37 | -211,341.61 | 245,713.46 | 156,876.25 |
| 六、净利润 | 105,176,469.82 | -7,803,212.71 | 34,239,781.33 | -3,459,530.47 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 105,176,469.82 | -7,803,212.71 | 34,239,781.33 | -3,459,530.47 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 105,176,469.82 | -7,803,212.71 | 34,239,781.33 | -3,459,530.47 |
| 扣除非经常损益后的净利润 | -48,862,245.08 | -7,563,796.43 | -28,131,923.26 | -22,592,063.89 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.14 | -0.01 | 0.05 | -0.01 |
| (二)稀释每股收益 | 0.14 | -0.01 | 0.05 | -0.01 |
| 八、其他综合收益 | - | - | 598,381.19 | 598,381.19 |
| 归属于母公司股东的其他综合收益 | - | - | 598,381.19 | 598,381.19 |
| 九、综合收益总额 | 105,176,469.82 | -7,803,212.71 | 34,838,162.52 | -2,861,149.28 |
| 归属于母公司股东的综合收益总额 | 105,176,469.82 | -7,803,212.71 | 34,838,162.52 | -2,861,149.28 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-04-25 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |